-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Benzinga·01/13/2025 15:54:47
Listen to the news
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.